Miragen Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch MGEN and buy or sell other stocks, ETFs, and their options commission-free!About MGEN
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis.
CEOStephen Frank Mahoney, MBA
CEOStephen Frank Mahoney, MBA
Employees143
Employees143
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2006
Founded2006
Employees143
Employees143
MGEN Key Statistics
Market cap1.89B
Market cap1.89B
Price-Earnings ratio-9.05
Price-Earnings ratio-9.05
Dividend yield—
Dividend yield—
Average volume1.58M
Average volume1.58M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$34.04
52 Week high$34.04
52 Week low$9.90
52 Week low$9.90
Stock Snapshot
With a market cap of 1.89B, Miragen Therapeutics(MGEN) trades at $23.01. The stock has a price-to-earnings ratio of -9.05.
On 2026-01-14, Miragen Therapeutics(MGEN) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Miragen Therapeutics(MGEN) stock has reached 0, versus its average volume of 1.58M.
Over the past 52 weeks, Miragen Therapeutics(MGEN) stock has traded between a high of $34.04 and a low of $9.90.
Over the past 52 weeks, Miragen Therapeutics(MGEN) stock has traded between a high of $34.04 and a low of $9.90.
People also own
Based on the portfolios of people who own MGEN. This list is generated using Robinhood data, and it’s not a recommendation.